- $500.80bn
- $565.10bn
- $61.16bn
US regulators to examine testosterone therapy as use by menopausal women rises
Focus: Testosterone scripts for women rise, along with denials and delays
Brief: AbbVie Declares Quarterly Cash Dividend Of $1.73 Per Share
AbbVie's menstrual migraine treatment meets late-stage study goal (updated)
Refile: AbbVie's migraine treatment meets late-stage study goal
AbbVie's blood cancer therapy lowers disease progression, death risk in trial (updated)
AbbVie's blood cancer drug meets late-stage trial goals
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Abbvie Submits EMA Application For Skyrizi Subcutaneous Induction In Adult Crohn's Disease
U.S. RESEARCH ROUNDUP-Amgen, Analog Devices, Moderna
Factbox: Global drugmakers invest billions to boost US presence
Factbox: Global drugmakers invest billions to boost US presence
Wall Street warms to healthcare stocks as tech trade faces turbulence
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Abbvie Inc reports results for the quarter ended June 30 - Earnings Summary